RT Journal Article
SR Electronic
T1 Antibody response to a fourth mRNA Covid-19 vaccine boost in weak responder kidney transplant recipients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.03.21262691
DO 10.1101/2021.09.03.21262691
A1 Sophie Caillard
A1 Olivier Thaunat
A1 Ilies Benotmane
A1 Christophe Masset
A1 Gilles Blancho
A1 on behalf of the French-speaking Society of Transplantation
YR 2021
UL http://medrxiv.org/content/early/2021/09/15/2021.09.03.21262691.abstract
AB The US FDA has recently authorized immunocompromised people to receive a third dose of mRNA Covid-19 vaccine following the two-doses regimen to further boost protection. Unfortunately, a non-negligible proportion of people treated with immunosuppressive drugs either do not respond or show only a weak response after a third boost and should, therefore, still be considered at risk of severe Covid-19. As of June 2021, we were granted the opportunity to offer a fourth vaccine dose to French solid organ transplant recipients who still showed a weak antibody response after the third dose. In this multicenter study, we demonstrate that that the protection conferred by a fourth dose is adequate for the majority of kidney transplant recipients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local Institutional Review Board (approval number: DC‐2013‐1990)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request